Dupilumab efficacy in uncontrolled, moderate-to-serve allergic asthma in the phase 3 liberty asthma quest study

Dupilumab efficacy in uncontrolled, moderate-to-serve allergic asthma in the phase 3 liberty asthma quest study

Dades bibliogràfiques
Autors principals:	Castro, M, Corren, J, Hanania, N, Pavord, I, Quirce, S, Thangavelu, K, Rice, M, O'Riordan, T, Maroni, J, Rowe, P, Lu, Y, Amin, N, Ruddy, M, Akinlade, B, Graham, N, Teper, A
Format:	Conference item
Publicat:	Elsevier 2018

Ítems similars

Dupilumab reduces severe exacerbation rate and improves lung function in adolescent patients with uncontrolled, moderate-to-severe asthma: from the Liberty Asthma Quest study
per: Maspero, J, et al.
Publicat: (2018)

A randomized, controlled phase 3 study, Liberty Asthma Quest, evaluating the efficacy and safety of dupilumab in uncontrolled moderate-to-severe asthma
per: Castro, M, et al.
Publicat: (2018)

Dupilumab reduces risk of severe exacerbations and improves FEV1 in patients on both high- and medium dose ICS with uncontrolled, moderate-to-severe asthma from the phase 3 LIBERTY ASTHMA QUEST Study
per: Pavord, I, et al.
Publicat: (2018)

Type 2 biomarkers associated with dupilumab efficacy in patients with uncontrolled, moderate-to-severe asthma enrolled in the phase 3 study LIBERTY ASTHMA QUEST
per: Wenzel, SE, et al.
Publicat: (2018)

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
per: Mario Castro, et al.
Publicat: (2020-01-01)

Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study
per: Yuji Tohda, et al.
Publicat: (2020-10-01)

Liberty asthma QUEST: Phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma
per: Busse, WW, et al.
Publicat: (2018)

Dupilumab efficacy and safety in moderate-to-severe uncontrolled Asthma
per: Castro, M, et al.
Publicat: (2018)

Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data
per: Sung-Hee Oh, et al.
Publicat: (2024-08-01)

Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis
per: Maspero, JF, et al.
Publicat: (2019)

Impact of Exacerbation History on Dupilumab Efficacy in Children with Uncontrolled Moderate-to-Severe Asthma: LIBERTY ASTHMA VOYAGE Study
per: Guilbert TW, et al.
Publicat: (2024-03-01)

Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study
per: Yuji Tohda, et al.
Publicat: (2023-01-01)

Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
per: Corren J, et al.
Publicat: (2023-03-01)

Azithromycin in uncontrolled asthma
per: Brusselle, G, et al.
Publicat: (2017)

Dupilumab in the management of moderate-to-severe asthma: the data so far
per: Barranco P, et al.
Publicat: (2017-09-01)

Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design
per: Lucia De Prado Gomez, et al.
Publicat: (2023-03-01)

Dupilumab Efficacy and Safety as an Add-On Therapy in Uncontrolled Asthma Patients: A Systematic Review
per: Evelyn Evelyn, et al.
Publicat: (2022-11-01)

Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics
per: Busse WW, et al.
Publicat: (2023-04-01)

Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation
per: Hanania NA, et al.
Publicat: (2022-06-01)

Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma
per: Jonathan Corren, et al.
Publicat: (2023-10-01)

Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils
per: Eugene R. Bleecker, et al.
Publicat: (2023-01-01)

Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials
per: Xiao-feng Xiong, et al.
Publicat: (2019-05-01)

The Role of Dupilumab in Severe Asthma
per: Fabio Luigi Massimo Ricciardolo, et al.
Publicat: (2021-08-01)

Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma
per: Gurnell M, et al.
Publicat: (2024-01-01)

Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma
per: Trivedi, A, et al.
Publicat: (2016)

A Case of Uncontrolled Asthma
per: Ömür Aydin M.D., et al.
Publicat: (2011-04-01)

Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function
per: Pavord ID, et al.
Publicat: (2020-12-01)

Experience of using dupilumab in the treatment of severe asthma
per: G. L. Ignatova, et al.
Publicat: (2020-09-01)

Controversies in allergy: should severe asthma with eosinophilic phenotype always be treated with anti-IL-5 therapies
per: Pavord, I, et al.
Publicat: (2019)

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR
per: Laidlaw TM, et al.
Publicat: (2023-09-01)

Dupilumab-associated hypereosinophilia in severe asthma
per: April Strong, et al.
Publicat: (2024-07-01)

Severe pediatric asthma therapy: Dupilumab
per: Giuliana Ferrante, et al.
Publicat: (2022-11-01)

Dupilumab: a novel treatment for asthma
per: Vatrella A, et al.
Publicat: (2014-09-01)

Efficacy of asthma education program on asthma control in children with uncontrolled asthma
per: Zeynep Arıkan-Ayyıldız, et al.
Publicat: (2016-08-01)

Repeated exacerbation of asthma: An intrinsic phenotype of uncontrolled asthma
per: Neeraj Jain, et al.
Publicat: (2019-01-01)

Socio-psychological problems in adolescents with uncontrolled bronchial asthma
per: L. S. Evert, et al.
Publicat: (2025-01-01)

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR [Corrigendum]
per: Laidlaw TM, et al.
Publicat: (2023-09-01)

UNCONTROLLED BRONCHIAL ASTHMA IN CHILDREN
per: L.S. Namazova-Baranova
Publicat: (2009-08-01)

UNCONTROLLED BRONCHIAL ASTHMA IN CHILDREN
per: L.S. Namazova-Baranova
Publicat: (2009-08-01)

Efficacy of tezepelumab against uncontrolled severe non‐type 2 asthma refractory to bronchial thermoplasty, benralizumab, dupilumab and mepolizumab
per: Yoshiro Kai, et al.
Publicat: (2024-03-01)